Last reviewed · How we verify
NCT06811844
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
Phase 2 trial testing Two-cycle induction chemotherapy + immunotherapy in Nasopharyngeal Neoplasms in 208 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | The First Affiliated Hospital of Xiamen University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 208 |
| Start date | 25 February 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2029 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Two-cycle induction chemotherapy + immunotherapy — full drug profile →
- Three-cycle induction chemotherapy + immunotherapy — full drug profile →
Conditions studied
- Nasopharyngeal Neoplasms — all drugs for Nasopharyngeal Neoplasms →
- PD-1 Inhibitor — all drugs for PD-1 Inhibitor →
- Induction Therapy — all drugs for Induction Therapy →
- Complete Response — all drugs for Complete Response →
Sponsor
The First Affiliated Hospital of Xiamen University
Who can join
Adults 18 to 65, any sex, with Nasopharyngeal Neoplasms or PD-1 Inhibitor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined with camrelizumab in patients with locally advanced nasopharyngeal carcinoma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Divergent immuno-landscapes: comparing the tumor microenvironment of Indian and Western HNSCC patients.
Kumar Rai P, Choudhary B. · · 2026 · PMID 42111272 · DOI 10.3389/fcell.2026.1725978
Verify or expand the search:
- PubMed search for NCT06811844
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nasopharyngeal Neoplasms
Currently open trials in the same condition.
- NCT07326358 — AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study · recruiting
- NCT05807880 — Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma · Phase 2 · active not recruiting
- NCT06019130 — Nivolumab in Children and Adults With Nasopharyngeal Carcinoma · Phase 2 · recruiting
- NCT03840421 — GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma · Phase 3 · active not recruiting
Other The First Affiliated Hospital of Xiamen University trials
Trials by the same sponsor.
- NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
- NCT07486492 — Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer · EARLY_PHASE1 · not yet recruiting
- NCT07458906 — DLL3-Targeted PET/CT in Neuroendocrine Carcinoma · NA · recruiting
- NCT07137052 — Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar · not yet recruiting
- NCT07189884 — Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06811844 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xiamen University
- Last refreshed: 1 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06811844.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing